Compare BIO-TECHNE Corp (TECH) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard S&P 500 ETF — how do they compare? BIO-TECHNE Corp trades at $72.45 (market cap $11.36B), while Vanguard S&P 500 ETF trades at $715.42 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 158.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 64 Days and Vanguard S&P 500 ETF for 55 Days on average.
| TECH | VOO | |
|---|---|---|
Market Cap | $11.36B | $1.80T |
Volume | 5,390,331 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $72.61 | $716.17 |
52-Week Low | $43.31 | $580.93 |
Typical Hold Time | 64 Days | 55 Days |
Enterprise Value | $11.39B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
VOO trades at $713.62, down slightly by 0.11% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 68.50 suggesting mild overbought conditions. Recent news highlights VOO's role in long-term wealth building through capital growth rather than dividends, with one article positioning it as a recession-resistant holding.
VOO offers diversified exposure to S&P 500 companies with strong institutional backing. Key risks include market volatility from interest rate uncertainty and potential earnings growth slowdown from 35% to 15% in 2027. The ETF remains a core holding for long-term investors despite short interest increasing 46.9% in September.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
